| Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-21 | 37,417.00 | (265.00) | 8.00¢ | 1,452.5 | n/a | -97% | 287.00¢ | 2.5% |
| 31-Dec-22 | 44,351.00 | 2,501.00 | 212.00¢ | 70.9 | 0.0 | +2,550% | 290.00¢ | 1.9% |
| 31-Dec-23 | 45,811.00 | 6,899.00 | 726.00¢ | 19.6 | 0.1 | +242% | 290.00¢ | 2.0% |
| 31-Dec-24 | 54,073.00 | 8,691.00 | 454.00¢ | 30.9 | n/a | -38% | 310.00¢ | 2.2% |
| 31-Dec-25 | 58,739.00 | 12,402.00 | 660.00¢ | 28.0 | 0.6 | +45% | 320.00¢ | 1.7% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Astrazeneca posts strong YTD beat, reiterates FY... | 30-Oct-2026 |
| Astrazeneca's Enhertu secures EU approval | 27-Oct-2026 |
| Astrazeneca's Ultomiris wins accelerated US appr... | 22-Oct-2026 |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Price | 13,960.00p |
| Change Today | 908.00p |
| 52 Week High | 15,316.00p |
| 52 Week Low | 11,460.00p |
| Volume | 4,546,444 |
| Shares Issued | 1,551.05m |
| Market Cap | £216,527m |
| Strong Buy | 10 |
| Buy | 8 |
| Neutral | 5 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 23 |
